SCHEMBL1633642

SCHEMBL1633642

CC(=O)Nc1cc(NC(C)=O)cc(Nc2ncc3ccc(OC4CCNCC4)cc3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 2/20 0.48
IKBKB O14920 1/20 0.44
SCN9A Q15858 1/20 0.44
MAP4K1 Q92918 2/20 0.44
GSK3B P49841 7/20 0.42
DYRK1A Q13627 7/20 0.42
WNT1 P04628 5/20 0.42
SYK P43405 2/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41
BRAF P15056 1/20 0.40
ABL1 P00519 2/20 0.40
HPGDS O60760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634760 0.92 MAP3K5 (0.54) MAP3K5IKBKBSCN9AMAP4K1GSK3B
SCHEMBL1633202 0.87 MAP4K1 (0.54) MAP3K5IKBKBSCN9AMAP4K1GSK3B
SCHEMBL1632083 0.84 IKBKB (0.47) IKBKBSYKJAK2JAK1TYK2
SCHEMBL1633269 0.83 IKBKB (0.48) IKBKBDYRK1ASYKJAK2JAK1
SCHEMBL13498327 0.82 IKBKB (0.43) IKBKBSYKJAK2JAK1TYK2
SCHEMBL1633623 0.81 TBK1 (0.51) IKBKBGSK3BDYRK1AWNT1JAK2
SCHEMBL1633616 0.81 IKBKB (0.48) IKBKBMAP4K1DYRK1ASYKJAK2
SCHEMBL12724910 0.80 SYK (0.49) IKBKBSYKJAK2JAK1TYK2
SCHEMBL1634175 0.79 SYK (0.53) IKBKBSYKJAK2JAK1TYK2
SCHEMBL1634539 0.78 IKBKB (0.44) IKBKBMAP4K1GSK3BDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed